Promis Neurosciences/ CA74346M1095 /
- - | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
-USD | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | - | - |
GlobeNewswire
30/04
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-D...
GlobeNewswire
09/04
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pat...
GlobeNewswire
01/04
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
GlobeNewswire
22/01
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
GlobeNewswire
20/11/2023
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s ...
GlobeNewswire
14/11/2023
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
GlobeNewswire
06/09/2023
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire
24/03/2022
ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit
GlobeNewswire
22/03/2022
ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 202...
GlobeNewswire
10/03/2022
ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s ...
GlobeNewswire
02/03/2022
ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of...
GlobeNewswire
03/02/2022
ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its ...
GlobeNewswire
27/01/2022
ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its...